TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3551673

Group type: EXPERIMENTAL
Intervention: Elimination diet (no cow milk and no egg from week 28 to delivery, with extra calcium and casein hydrolysate supplement)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Elimination diet
Number of subjects: 212

Group type: COMPARATOR
Intervention: Normal food (including approximately 1/2 liter of milk/day and 3‐5 eggs/week)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Normal food
Number of subjects: 212
Study: 31243691

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 1162

Group type: EXPERIMENTAL
Intervention: Educational program
Number of subjects: 1162

Group type: EXPERIMENTAL
Intervention: Continued educational program
Number of subjects: 1162

Group type: EXPERIMENTAL
Intervention: Secondary SOC
Number of subjects: 1162
Study: 29153451

Group type: EXPERIMENTAL
Intervention: Novel minimally invasive surgery combined with Kazakh exercise therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Continuous medial oblique surgical approach (Control)
Number of subjects: 52
Study: 27643171

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg/d
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Indapamide 1.5 mg/d
Number of subjects: 140
Study: 25244465

Group type: EXPERIMENTAL
Intervention: Reasoning training intervention
Number of subjects: 1375

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1375
Study: 22331583

Group type: EXPERIMENTAL
Intervention: Ostracism condition
Number of subjects: 58

Group type: COMPARATOR
Intervention: Included condition
Number of subjects: 58
Study: 20664293

Group type: EXPERIMENTAL
Intervention: SNCA REP1 259 genotype (homozygous or heterozygous)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SNCA REP1 263 genotype (homozygous or heterozygous)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SNCA variations with pesticide exposure and smoking
Number of subjects: 0
Study: 17573489

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg)
Number of subjects: 47
Study: 15757965

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg every 6 weeks up to week 156
Number of subjects: 49
Study: 12120881

Group type: EXPERIMENTAL
Intervention: Thiamphenicol glycinate hydrochloride (TGH) 1500 mg daily for 10 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clarithromycin 1000 mg daily for 10 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Thiamphenicol glycinate hydrochloride (TGH)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Thiamphenicol glycinate hydrochloride (TGH) and Clarithromycin
Number of subjects: 40
Study: 10440204

Group type: EXPERIMENTAL
Intervention: Conformal breast shield during radiotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard breast radiotherapy without shield
Number of subjects: 20
Study: 7784789

Group type: EXPERIMENTAL
Intervention: Budesonide dry powder (200 micrograms)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Budesonide dry powder (400 micrograms)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 micrograms)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms) vs Budesonide (400 micrograms)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Budesonide (200 micrograms) vs Fluticasone propionate (200 micrograms)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms) vs Fluticasone propionate (200 micrograms)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: All active treatments
Number of subjects: 98
Study: 2125938

Group type: EXPERIMENTAL
Intervention: Acipimox (AC) 500 mg with placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: Acetylsalicylic acid 1500 mg and AC 500 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (NIC) 500 mg with placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Acipimox (AC) 500 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Acetylsalicylic acid 1500 mg
Number of subjects: 9
Study: 7013865

Group type: EXPERIMENTAL
Intervention: Prednisone, Vincristine, Daunorubicin or the same plus Cyclophosphamide for induction and reinductions
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Intrathecal Methotrexate
Number of subjects: 405

Group type: COMPARATOR
Intervention: Intrathecal Methotrexate plus Ara‐C
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: L‐Asparaginase consolidation
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: 6‐Mercaptopurine and Methotrexate maintenance
Number of subjects: 405
Study: 30665323

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months for 12 months
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo every 6 months for 12 months
Number of subjects: 63
Study: 27923565

Group type: EXPERIMENTAL
Intervention: Sound generator (SG) with counseling; assessed at three stages: initial, monitoring, and final (6 months after adaptation).
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sound generator (SG) with hearing aid (HA) and counseling; assessed at three stages: initial, monitoring, and final (6 months after adaptation).
Number of subjects: 30
Study: 25294665

Group type: EXPERIMENTAL
Intervention: Resistance training program of unilateral knee extensions for 12 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Model simulation of aponeurosis width increase
Number of subjects: 11
Study: 24321801

Group type: EXPERIMENTAL
Intervention: Beclometasone 100 μg plus formoterol 6 μg as maintenance and reliever treatment
Number of subjects: 1714

Group type: COMPARATOR
Intervention: Salbutamol 100 μg as reliever
Number of subjects: 1714
Study: 21781653

Group type: EXPERIMENTAL
Intervention: Test formulation (Tonafil®)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference formulation (Viagra®)
Number of subjects: 20
Study: 19657123

Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg orally twice daily
Number of subjects: 3195

Group type: COMPARATOR
Intervention: Enoxaparin 30 mg subcutaneously every 12 hours
Number of subjects: 3195

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 3195

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 3195
Study: 17526195

Group type: EXPERIMENTAL
Intervention: Biasten (budesonide plus salbutamol hemisuccinate)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Benacort (budesonide) plus Salben (salbutamol)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both interventions (Biasten and Benacort plus Salben)
Number of subjects: 46
Study: 15888150

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 166

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 166
Study: 12784089

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (CT; 200 U/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 20
Study: 10532516

Group type: EXPERIMENTAL
Intervention: Fluvastatin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8682483

Group type: EXPERIMENTAL
Intervention: r‐IFN alpha‐2a (5 million units, subcutaneously, thrice weekly)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: r‐IFN alpha‐2b (5 million units, subcutaneously, thrice weekly)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 18
Study: 1830462

Group type: COMPARATOR
Intervention: Propofol induction and propofol-nitrous oxide maintenance (control)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Propofol induction and desflurane-nitrous oxide maintenance
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Desflurane-nitrous oxide
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Desflurane alone for induction and maintenance
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Desflurane in oxygen
Number of subjects: 92
Study: 6122694

Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Caffeine citrate (125 to 500 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Caffeine citrate (500 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31213771

Group type: COMPARATOR
Intervention: 2% lidocaine hydrochloride (1.5 mg/kg) infused intravenously (Group I)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: 2% lidocaine hydrochloride (1.5 mg/kg) dripped into the tracheostomy tube (Group II)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: 7% lidocaine aerosol (5 sprays, 22.5mg) sprayed into the tracheostomy incision (Group III)
Number of subjects: 115
Study: 28985239

Group type: EXPERIMENTAL
Intervention: 3 × 104 PFU
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 3 × 105 PFU
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 3 × 106 PFU
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 2 × 107 PFU
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 2 × 107 PFU (adolescents)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 2 × 107 PFU (children)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: ≥3 × 105 PFU
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 2 × 107 PFU (adolescents and children)
Number of subjects: 155
Study: 27488181

Group type: EXPERIMENTAL
Intervention: Blended depression treatment combining mobile and Internet technologies with face-to-face treatment
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 1200
Study: 24380796

Group type: EXPERIMENTAL
Intervention: HDHK intervention (n=48 fathers, n=72 children)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: HDHK intervention
Number of subjects: 93

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 93
Study: 22595799

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once daily
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study: 19709404

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (four sessions)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 50
Study: 17159193

Group type: EXPERIMENTAL
Intervention: Upfront zoledronic acid (4 mg intravenously every 6 months)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Delayed zoledronic acid (administered when LS or TH T score decreased to less than -2.0 or when a nontraumatic fracture occurred)
Number of subjects: 602
Study: 15901026

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA) with propofol-remifentanil
Number of subjects: 27

Group type: COMPARATOR
Intervention: Inhaled anesthetic group (propofol-fentanyl-isoflurane)
Number of subjects: 27
Study: 11953965

Group type: EXPERIMENTAL
Intervention: Pyramid treatment strategy (initial NSAIDs, followed by chloroquine or sulfasalazine)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Immediate treatment with chloroquine or sulfasalazine
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Combination treatment with step-down prednisolone, methotrexate, and sulfasalazine (COBRA trial)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Sulfasalazine alone (COBRA trial)
Number of subjects: 361
Study: 9857661

Group type: EXPERIMENTAL
Intervention: Prednisone treatment (20 mg/d for 14 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy control subjects (N=22)
Number of subjects: 20
Study: 7609198

Group type: EXPERIMENTAL
Intervention: 2-stage epispadias reconstruction with dissection of the corporo (30 patients)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: pedicled preputial tube urethroplasty either alone or with a lyophilized human dural patch (35 patients)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: pedicled preputial tube urethroplasty and corporeal rotation (40 patients)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: modified Cantwell epispadias repair incorporating complete tubularized urethroplasty, cavernocavernostomy and corporeal rotation
Number of subjects: 180
Study: 2172175

Group type: EXPERIMENTAL
Intervention: 200 mg/kg body weight FDP
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 419426

Group type: EXPERIMENTAL
Intervention: Povidone-iodine solution irrigation
Number of subjects: 500

Group type: COMPARATOR
Intervention: Saline solution irrigation
Number of subjects: 500
Study: 30760183

Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition (late-PN)
Number of subjects: 982

Group type: COMPARATOR
Intervention: Early parenteral nutrition (early-PN)
Number of subjects: 982
Study: 27574821

Group type: EXPERIMENTAL
Intervention: mpMRI/transrectal ultrasound fusion software‐guided targeted biopsy (TB)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Standard biopsy (SB)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: TB in arm A
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: SB in arm A
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: SB in arm B
Number of subjects: 212
Study: 25789261

Group type: EXPERIMENTAL
Intervention: Propofol 20 mg
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Propofol 30 mg
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 23982635

Group type: EXPERIMENTAL
Intervention: Harvesting the semitendinosus tendon only
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Harvesting the semitendinosus and gracilis tendons
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Regenerated semitendinosus tendon
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Isokinetic strength assessment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Macroscopic and histological analysis of regenerated tendons
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Use of regenerated tendon
Number of subjects: 150
Study: 21353334

Group type: EXPERIMENTAL
Intervention: Clobetasol
Number of subjects: 38

Group type: COMPARATOR
Intervention: Pimecrolimus
Number of subjects: 38
Study: 19636533

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (target BG 4.4-6.1 mmol/L)
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Intermediate glucose control (target BG 7.8-10.0 mmol/L)
Number of subjects: 1078
Study: 17470885

Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg iv
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ondansetron 4 mg iv
Number of subjects: 90
Study: 15743156

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (five educational sessions)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Medical recommendations (standard written diet instructions)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 140

Group type: COMPARATOR
Intervention: Medical recommendations
Number of subjects: 140

Group type: COMPARATOR
Intervention: Nutritional intervention and Medical recommendations
Number of subjects: 140
Study: 11552910

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pneumatic dilatation
Number of subjects: 40
Study: 9558744

Group type: EXPERIMENTAL
Intervention: Polyen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 7631085

Group type: EXPERIMENTAL
Intervention: Motor cortex stimulation (3 patients); pulse duration 0.1‐0.5 ms; intensity 3‐8 V
Number of subjects: 6

Group type: COMPARATOR
Intervention: Thalamic stimulation (4 patients)
Number of subjects: 6
Study: 2889459

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevantolol (200 mg)
Number of subjects: 0
Study: 30105967

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate (PA)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: db-PCR-NALFIA
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: qPCR
Number of subjects: 146
Study: 28267591

Group type: EXPERIMENTAL
Intervention: Stress condition (Trier Social Stress Test)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control condition (friendly TSST)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 63
Study: 26387392

Group type: EXPERIMENTAL
Intervention: Malvastrum coromandelianum (MC) tablets, 1,200 mg/day for 12 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 22297124

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study: 21160309

Group type: EXPERIMENTAL
Intervention: Rehabilitation program with early mobilization and diet (n = 46)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional care (n = 54)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rehabilitation program with early mobilization and diet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 100
Study: 18996881

Group type: EXPERIMENTAL
Intervention: B-GOS (5.5 g/d)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 17167301

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Weight training (WT)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Health educational (HE)
Number of subjects: 435
Study: 14599072

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 32
Study: 12654764

Group type: EXPERIMENTAL
Intervention: ABT-773 (cethromycin) at a dose of 150 mg once a day for 10 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: ABT-773 (cethromycin) at a dose of 150 mg twice a day for 10 days
Number of subjects: 10
Study: 9623220

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8122724

Group type: EXPERIMENTAL
Intervention: Defibrillation by emergency medical technicians (EMTs) trained in Defibrillation (study group = S)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Basic life support (BLS) by EMTs and defibrillation by emergency physicians (control group 1 = C1)
Number of subjects: 121

Group type: COMPARATOR
Intervention: BLS and advanced cardiac life support (ACLS) by emergency physician crews (control group 2 = C2)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Defibrillation by EMTs (study group = S)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Defibrillation by emergency physicians (control group 1 = C1)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Defibrillation by emergency physicians (control group 2 = C2)
Number of subjects: 121
Study: 2511743

Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem 120 mg twice daily
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem 180 mg twice daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 125389

Group type: EXPERIMENTAL
Intervention: Caffeine coadministration with levodopa
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Caffeine coadministration with piribedil
Number of subjects: 6
Study: 31485817

Group type: EXPERIMENTAL
Intervention: Dietary behavior
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 1038
Study: 28220376

Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Divalproex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valproate
Number of subjects: 0
Study: 26281341

Group type: EXPERIMENTAL
Intervention: Local infiltration anesthesia (LIA)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Peripheral nerve block (PNB)
Number of subjects: 54
Study: 22388589

Group type: EXPERIMENTAL
Intervention: Telephone-based peer support (mother-to-mother)
Number of subjects: 349
Study: 22090477

Group type: EXPERIMENTAL
Intervention: LY2811376, an orally available non-peptidic BACE1 inhibitor, dosages of 30 mg and 90 mg.
Number of subjects: 0
Study: 19723732

Group type: EXPERIMENTAL
Intervention: Life Goals Program (LGP)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 164
Study: 17250885

Group type: EXPERIMENTAL
Intervention: Words
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Gestures
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Words and Gestures
Number of subjects: 2
Study: 15180223

Group type: EXPERIMENTAL
Intervention: Pain management program
Number of subjects: 188
Study: 11677506

Group type: EXPERIMENTAL
Intervention: Educational intervention during waiting time
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual clinic care (no structured education)
Number of subjects: 100
Study: 10218061

Group type: EXPERIMENTAL
Intervention: Sorbitol/xylitol-sweetened chewing gum
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sorbitol-sweetened sour lemon lozenge
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sorbitol/xylitol-sweetened artificial saliva substitute spray
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (baseline paraffin-stimulated mean flow rate)
Number of subjects: 80
Study: 8160944

Group type: EXPERIMENTAL
Intervention: Indomethacin suppositories 200 mg p.r. at the end of anaesthesia, followed by 100 mg bd for three days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo suppositories according to the same regimen
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Indomethacin group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 3410354

Group type: EXPERIMENTAL
Intervention: Wide local excision with ipsilateral superficial inguinal lymph node dissection
Number of subjects: 22

Group type: COMPARATOR
Intervention: Radical vulvectomy with bilateral superficial and deep inguinal lymph node dissection
Number of subjects: 22
Study: 31130268

Group type: EXPERIMENTAL
Intervention: Coblation Radiofrequency (CR)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Coblation Submucosal Reduction Turbinator (SCT)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 57
Study: 27794124

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab
Number of subjects: 1392

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1392